Our annual summer outing at Fenway Park was a hit! ⚾ Enjoying quality time with colleagues, along with their friends and families reinforces the positive and supportive environment we've cultivated here at Tessera. We believe these moments of team bonding contribute to enhanced trust, productivity, and a foundation for continued success. #TeamTessera #SummerOuting #Redsox #CompanyCulture #Community
About us
Our Gene Writing™ technology advances genetic medicine beyond its current limitations. Learn more at http://TesseraTherapeutics.com
- Website
-
http://tesseratx.com
External link for Tessera Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Somerville, MA
- Type
- Privately Held
Locations
-
Primary
Somerville, MA 02143, US
Employees at Tessera Therapeutics
Updates
-
Exciting news from Flagship Pioneering as they announce the raise of $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be #FlagshipFounded and part of an ecosystem of companies – present and future – taking bold scientific leaps to deliver a better future for all. Hear more from Flagship Founder and CEO Noubar Afeyan: https://lnkd.in/egcEgNrR
-
In case you missed it, we announced non-human primate data showing therapeutically relevant levels of in vivo rewriting of the gene responsible for alpha-1 antitrypsin deficiency at the Federation of American Societies for Experimental Biology (FASEB) 2024 Genome Engineering conference. Read more about the data here: https://lnkd.in/edAJUStY
-
This June, our #TesserOUT ERG championed inclusion with a month of action. From marching in the Boston Pride Parade to hosting vibrant company-wide celebrations and partnering with LGBTQIA+-owned businesses, they fostered a welcoming community for all. At Tessera, we understand the journey for equality continues, and remain committed to building a more inclusive future, year-round. Learn more about life at Tessera: https://bit.ly/4bbx3ZA #Pride2024 #TeamTessera #Inclusion #Diversity
-
This year at the 2024 #MontySummit, our CEO, Michael Severino, spoke about the potential impact of #GeneticMedicine on patients living with serious diseases. At Tessera, we're building the #FutureofGeneticMedicine, a field we believe will become a new pillar in medicine.
In reflecting on their journey as a physician scientist, Michael Severino, CEO of Tessera Therapeutics shared firsthand accounts of the profound impact of genetic medicine at the 2024 #MontySummit. Originally trained as an HIV immunologist, Severino grappled with the limitations of traditional treatments when faced with devastating diseases. As we navigate the frontier of genetic medicine, key questions emerge: How can scientific innovation be translated into practical solutions for patients? What strategies can address rare genetic diseases, advanced cancers, and more common ailments like Alzheimer's? The ability to transform despair into hope lays the foundation for success, not just in medical breakthroughs but also in building remarkable companies dedicated to genetic medicine. Genetic medicine has the potential to revolutionizes healthcare, offering hope to millions and curing once-incurable diseases. Discover more about the impact of genetic medicine on common diseases and breakthroughs in genetic therapy in the full 2024 Summit session on the future of medicine featuring Geoffrey von Maltzahn (Flagship Pioneering), Nicole K. Paulk, PhD (Siren Biotechnology) and Michael Severino. https://lnkd.in/gNQtFFrS #GeneticMedicine #HealthcareInnovation #MedicalBreakthroughs #FutureOfMedicine #Innovation #Technology
-
We’re attending Biotechnology Innovation Organization’s #BIO2024 conference! Anne-Virginie Eggimann, our Chief Regulatory Officer, will be speaking on a panel discussing the latest guidance in platform product innovation. Mark your calendars and register now: https://lnkd.in/eBVwb3gh
-
At #ASGCT2024, our CEO, Michael Severino, was featured on an episode of BiotechTV diving deeper into the remaining unmet need for patients with #SickleCellDisease and the rapid progress of our in vivo rewriting therapies toward the clinic. Watch the full episode for our latest advancements across our #GeneWriting and delivery platforms.
𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟒: In humanized mouse models, Tessera Therapeutics is demonstrating LNP delivery of gene writers to, and rewriting of, hematopoietic stem cells to an extent that could be curative in sickle cell disease. CEO Michael Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company's gene writing platform and programs more broadly. Full video: https://lnkd.in/gh2C4Wy2 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
May is #AAPI Heritage Month! The 2024 theme is “Advancing Leaders Through Innovation”, focused on expanding leadership opportunities for the AAPI community. Join us in celebrating the contributions of Asian Americans and Pacific Islanders in driving innovations in #GeneticMedicine and beyond.
-
We're honored to be included in this #FlagshipFounded recap list of companies who presented at #ASGCT2024 as we continue to write the #FutureofGeneticMedicine! Check out the full summary to learn more about our new preclinical data highlighting advancements across our platforms.
Flagship-founded companies joined other leaders in #cellandgenetherapy at the American Society of Gene & Cell Therapy's Annual Meeting, sharing strides in the development of their respective bioplatform technologies and progress toward potentially transformative medicines. Read the full summary and highlights below: https://lnkd.in/emmmbgbN 🔷 Ring Therapeutics shared data in nonhuman primates showing the ability to redose genetic medicines using their vectors based on a little-known class of viruses called anelloviruses. 🔷 Tessera Therapeutics displayed curative results in humanized mouse models using its Gene Writers and proprietary lipid nanoparticles to restore normal hemoglobin production in hematopoietic stem cells in the bone marrow without chemotherapy or mobilization for the treatment of #sicklecelldisease. 🔷 Alltrna demonstrated robust ability to readthrough premature stop codons in mouse models, promising preclinical results that suggest their engineered tRNAs could offer a versatile approach to rescue protein production in rare and ulta-rare diseases caused by nonsense mutations, known as stop codon disease. 🔷 Omega Therapeutics showed preclinical data highlighting their ability to program epigenetic controllers to upregulate gene expression for a variety of genes types and cell conditions, providing effects that last weeks to months after a single dose. 🔷 Sana Biotechnology, Inc. displayed data showing a promising safety profile for their in vivo CAR T therapy, suggesting its potential to offer comparable efficacy and genomic safety as established treatments.
Flagship at ASGCT 2024
flagshippioneering.com
-
Thank you to the American Association of Pharmaceutical Scientists (AAPS) | @aapscomms for providing Hari Pujar, our COO, with the opportunity to lead the opening plenary session at #NBC2024 on next-generation approaches to #biotechnology modality development! We're excited to be part of this year’s National Biotechnology Conference as we pioneer the #FutureofGeneticMedicine.
👋 Welcome to the first day of the National Biotechnology Conference, #NBC2024! Join us for the Opening Plenary in just a few hours that features Hari Pujar, Ph.D., of Tessera Therapeutics, discussing his company's advancements in #genome engineering. Register now!
NBC 2024 Starts Today!
aaps.org